Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus Stupp Regimen in Newly Diagnosed Glioblastoma
NCT04157478Phase 2Unknown
- Sponsor
- Guangxi Zhuang Autonomous Region People's Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib in glioblastoma (GBM) (2 arms), sponsored by Guangxi Zhuang Autonomous Region People's Hospital. Primary endpoint: Progression-free survival at 3 years. Status: unknown.
02
Drugs
anlotinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04157478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04157478.